Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YELLIANN RUIZ IRIZARRY

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1083846893
CMS profile
508170
Location
PALMETTO BAY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,055.20

45 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,055.20 45

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $303.35 18
Mallinckrodt Hospital Products Inc. $206.62 8
Janssen Biotech, Inc. $121.87 1
ANI Pharmaceuticals, Inc. $113.88 5
AbbVie Inc. $66.51 3
Kiniksa Pharmaceuticals, Ltd. $61.55 2
UCB, Inc. $44.99 2
Radius Health, Inc. $43.44 2
Lilly USA, LLC $30.38 1
Horizon Therapeutics plc $28.97 1
GlaxoSmithKline, LLC. $20.69 1
Sandoz Inc. $12.95 1

Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YELLIANN RUIZ IRIZARRY

NPI 1083846893 · CMS profile ID 508170

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

PALMETTO BAY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083846893?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YELLIANN RUIZ IRIZARRY, NPI 1083846893, CMS profile ID 508170. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083846893?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). YELLIANN RUIZ IRIZARRY, NPI 1083846893, CMS profile ID 508170. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083846893?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
YELLIANN RUIZ IRIZARRY, NPI 1083846893, CMS profile ID 508170, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1083846893?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

45 matching records · $1,055.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 45 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–45 of 45.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ANI Pharmaceuticals, Inc. $33.4812/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034181391 CMS
AbbVie Inc. $15.5011/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998733349 CMS
Mallinckrodt Hospital Products Inc. $34.3711/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042883179 CMS
Amgen Inc. $15.1611/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205267 CMS
Sandoz Inc. $12.9511/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1028958315 CMS
ANI Pharmaceuticals, Inc. $14.7111/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034147225 CMS
Amgen Inc. $13.7511/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205281 CMS
UCB, Inc. $20.0011/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021991277 CMS
AbbVie Inc. $26.0611/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998733345 CMS
Amgen Inc. $20.6511/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205263 CMS
Mallinckrodt Hospital Products Inc. $31.0710/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042883175 CMS
Kiniksa Pharmaceuticals, Ltd. $24.5810/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058946613 CMS
AbbVie Inc. $24.9510/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998733339 CMS
Amgen Inc. $21.1310/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205259 CMS
ANI Pharmaceuticals, Inc. $17.7810/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034107457 CMS
ANI Pharmaceuticals, Inc. $24.6110/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034141479 CMS
Amgen Inc. $18.5810/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205255 CMS
GlaxoSmithKline, LLC. $20.6910/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001683311 CMS
Mallinckrodt Hospital Products Inc. $34.8209/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042883169 CMS
Amgen Inc. $7.2809/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205251 CMS
Amgen Inc. $15.9309/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205277 CMS
Amgen Inc. $16.2909/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205246 CMS
Radius Health, Inc. $21.3308/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024721015 CMS
Amgen Inc. $8.1308/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205241 CMS
UCB, Inc. $24.9908/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021991281 CMS
Mallinckrodt Hospital Products Inc. $36.4108/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042883163 CMS
Amgen Inc. $19.9307/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205237 CMS
Amgen Inc. $21.8706/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205233 CMS
Kiniksa Pharmaceuticals, Ltd. $36.9706/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058946905 CMS
Mallinckrodt Hospital Products Inc. $26.6906/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042883157 CMS
Amgen Inc. $14.1805/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205229 CMS
Radius Health, Inc. $22.1105/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024721011 CMS
Mallinckrodt Hospital Products Inc. $10.1705/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042883151 CMS
Amgen Inc. $27.1805/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205225 CMS
Horizon Therapeutics plc $28.9704/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987068177 CMS
Amgen Inc. $17.9303/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205275 CMS
Amgen Inc. $14.2503/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205223 CMS
Amgen Inc. $18.1403/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205271 CMS
Amgen Inc. $9.7702/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205219 CMS
Amgen Inc. $23.2002/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020205213 CMS
Lilly USA, LLC $30.3802/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032653559 CMS
ANI Pharmaceuticals, Inc. $23.3001/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034166567 CMS
Mallinckrodt Hospital Products Inc. $29.1801/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042883139 CMS
Mallinckrodt Hospital Products Inc. $3.9101/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042883145 CMS
Janssen Biotech, Inc. $121.8701/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988120595 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $325.62 7
PY2020 $101.85 4
PY2021 $35.84 2
PY2022 $58.26 3
PY2023 $1,055.20 45
PY2024 $1,733.58 85
PY2025 $1,822.84 86

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $36,513.46 10
PY2022 Principal investigator $221,229.09 69
PY2021 Principal investigator $435,565.89 32
PY2020 Principal investigator $63,547.60 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $8,337.60 12/27/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 860868619
Principal investigator 1 ABBVIE INC. $2,353.63 12/02/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792485147
Principal investigator 1 GlaxoSmithKline, LLC. $14,813.10 12/01/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 860868621
Principal investigator 1 ABBVIE INC. $4,426.76 11/04/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792481311
Principal investigator 1 GlaxoSmithKline, LLC. $27,033.30 10/25/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809495121
Principal investigator 1 GlaxoSmithKline, LLC. $31,157.10 09/27/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809536769
Principal investigator 1 GlaxoSmithKline, LLC. $5,500.00 09/23/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 24-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, EFFICACY AN No dispute reported 06/30/2026 809516171
Principal investigator 1 GlaxoSmithKline, LLC. $5,500.00 09/03/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809536763
Principal investigator 1 ABBVIE INC. $2,820.47 09/01/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792473757
Principal investigator 1 GlaxoSmithKline, LLC. $21,671.10 09/01/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809503099
Principal investigator 1 ABBVIE INC. $10,424.39 07/29/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792470289
Principal investigator 1 GlaxoSmithKline, LLC. $24,475.50 07/23/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809483129
Principal investigator 1 Navidea Biopharmaceuticals, Inc. $6,250.00 07/23/2021 Non-covered Recipient Entity
Innovation Medical Research Center, Inc.
Development of a Normative Database for Rheumatoid Arthritis Imaging with Tc99m Tilmanocept No dispute reported 06/30/2026 854741585
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 07/16/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 24-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, EFFICACY AN No dispute reported 06/30/2026 809488609
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 07/16/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 24-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, EFFICACY AN No dispute reported 06/30/2026 809489885
Principal investigator 1 GlaxoSmithKline, LLC. $50,204.70 07/12/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809483125
Principal investigator 1 ABBVIE INC. $3,444.39 06/30/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792465279
Principal investigator 1 Navidea Biopharmaceuticals, Inc. $21,284.00 06/10/2021 Non-covered Recipient Entity
Innovation Medical Research Center, Inc.
Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value on Tc 99m Tilmanocept Planar Imaging No dispute reported 06/30/2026 854741581
Principal investigator 1 GlaxoSmithKline, LLC. $5,725.80 06/09/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809482651
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/09/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809488079
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 06/09/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809488563
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 06/04/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 809482741
Principal investigator 1 ABBVIE INC. $9,868.20 06/02/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792461679
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/02/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809482689
Principal investigator 1 GlaxoSmithKline, LLC. $1,700.00 06/02/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809489913
Principal investigator 1 ABBVIE INC. $12,196.52 04/29/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792450157
Principal investigator 1 ABBVIE INC. $3,693.66 04/02/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792442125
Principal investigator 1 ABBVIE INC. $72,529.08 03/31/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792440041
Principal investigator 1 ABBVIE INC. $60,441.40 03/17/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792433877
Principal investigator 1 ABBVIE INC. $8,846.90 03/02/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792429683
Principal investigator 1 ABBVIE INC. $7,268.29 01/28/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792415969
Principal investigator 1 GlaxoSmithKline, LLC. $5,500.00 01/08/2021 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 809486655